Autism Spectrum Disorders Clinical Trial
— RILISEOfficial title:
A Pilot Study of Riluzole vs. Placebo in the Treatment of Children and Adolescents With Autism Spectrum Disorders
Verified date | March 2017 |
Source | Anagnostou, Evdokia, M.D. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will examine the potential efficacy and safety of riluzole for core and associated symptom domains of autism and will explore biological markers of safety and treatment response.
Status | Completed |
Enrollment | 58 |
Est. completion date | October 2015 |
Est. primary completion date | September 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 17 Years |
Eligibility |
Inclusion Criteria: 1. Male or female outpatients 6-17 years of age inclusive, with a mental age equivalent = 18 months at Screening visit. 2. Meet Diagnostic and Statistical Manual (DSM-IV) criteria for an ASD. 3. Have a Clinician's Global Impression-Severity (CGI-S) score = 4 (moderately ill) at Screening. 4. If already receiving stable interventions must meet the following criteria: 1. If already receiving stable concomitant medications affecting behavior, must be on a stable dose during the preceding 1 month prior to Screening (with the exception of fluoxetine, where a period of 6 weeks is needed), and will not electively initiate new or modify ongoing medications for study duration. 2. If already receiving stable non-pharmacological educational, behavioral, and/or dietary interventions, have continuous participation during the preceding 3 months prior to Screening, and not electively initiate new or modify ongoing interventions for the duration of the study. 5. Have normal physical examination and laboratory test results at Screening. If abnormal, the finding(s) must be deemed clinically insignificant by the Investigator. 6. Ability to complete assessments- fluency in English (parent; patient, if verbal). 7. Consent to participate in the Province of Ontario Neurodevelopmental (POND) study and commitment to completing as many stages as possible of the phenotyping measures (Stages 1, 2 and 3), genomics component, and interest in being imaged through POND. 8. Ability to obtain written informed consent from the participant, if developmentally appropriate. If a participant does not have the capacity to consent, ability to obtain assent (if developmentally appropriate), as well as written informed consent from their parent(s)/legal guardian. Exclusion Criteria: 1. Pregnant female patients; sexually active female patients on inadequate birth control. 2. Patients with a serious medical condition that, based on Investigator judgment, might interfere with the conduct of the study, confound interpretation of the study results, or endanger their own well-being. Patients with evidence or history of malignancy or any significant hematological, endocrine, cardiovascular (including any rhythm disorder), respiratory, renal, hepatic, or gastrointestinal disease, not including mild common pediatric diseases in these areas that are stable (e.g. mild asthma, constipation, etc.). 3. Patients with unstable epilepsy (i.e. seizures occurring within the last 6 months), or patients with epilepsy who are not on stable doses of antiepileptic medications (i.e. dose changes within the last 3 months). 4. Patients with hypersensitivity to riluzole or any components of its formulation. 5. Patients with one or more of the following: HIV, Hepatitis B virus, Hepatitis C virus, hemophilia (bleeding problems, recent nose and brain injuries), abnormal blood pressure (hypotension or hypertension), drug abuse, immunity disorder, major depressive episode or psychosis. 6. Patients unable to tolerate venipuncture procedures for blood sampling. 7. Patients receiving concomitant medications that specifically target the glutamate system (e.g. memantine, d-cycloserine), or decrease the elimination of riluzole (e.g. theophylline, quinolones), less than 30 days prior to the screening visit. 8. Patients actively enrolled in another intervention study. 9. Patients who are unable to swallow pills. 10. Patients who have elevated liver enzymes = 3 times the normal amount before the study begins. |
Country | Name | City | State |
---|---|---|---|
Canada | Offord Centre for Child Studies | Hamilton | Ontario |
Canada | Lawson Health Research Institute | London | Ontario |
Canada | Holland Bloorview Kids Rehabilitation Hospital | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
Evdokia Anagnostou | Holland Bloorview Kids Rehabilitation Hospital, McMaster University, St. Michael's Hospital, Toronto, The Hospital for Sick Children, University of Toronto, University of Western Ontario, Canada |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy of riluzole vs. placebo on measures of social function | This will be measured by the Aberrant Behavior Checklist (ABC) - Lethargy / Social Withdrawal Subscale | 12 weeks | |
Primary | Efficacy of riluzole vs. placebo on measures of repetitive behaviors | This will be measured by the Child Yale-Brown Obsessive Compulsive Scale (CY-BOCS) | 12 weeks | |
Primary | Efficacy of riluzole vs. placebo on measures of repetitive behaviors | This will be measured by the Repetitive Behavior Scale (RBS-R) | 12 weeks | |
Primary | Safety and tolerability of riluzole in children and adolescents with ASD | This will be measured by the Safety Monitoring Uniform Report Form (SMURF) | 12 Weeks | |
Primary | Safety and tolerability of riluzole in children and adolescents with ASD | This will be measured by the Clinical Global Impressions - Improvement Scale - Global (CGI-I-Global) | 12 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02625116 -
ELENA Cohort: A Long-term Longitudinal Study in a Pediatric Sample With Autism Spectrum Disorders
|
||
Not yet recruiting |
NCT06381856 -
Improving Participation of Autistic Children and Adolescents in the Habilitation Process
|
||
Recruiting |
NCT02280746 -
Gluten for Autism Spectrum Disorders
|
N/A | |
Completed |
NCT01945957 -
Brain Imaging of Intranasal Oxytocin Treatment in Autism
|
Phase 1 | |
Completed |
NCT01592747 -
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
|
Phase 2 | |
Completed |
NCT01780090 -
Handheld Technology for Speech Development in Students With Autism
|
N/A | |
Completed |
NCT01694667 -
Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder
|
Phase 2 | |
Completed |
NCT01691066 -
Pivotal Response Treatment for Infants At-Risk for Autism Spectrum Disorder
|
N/A | |
Active, not recruiting |
NCT01417026 -
Intranasal Oxytocin and Learning in Autism
|
Phase 2 | |
Enrolling by invitation |
NCT01364818 -
Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment
|
N/A | |
Completed |
NCT01695200 -
Omega-3 Fatty Acids in Autism Spectrum Disorders
|
Phase 4 | |
Completed |
NCT02300597 -
Internet-based Support for Young People With ADHD and Autism - a Controlled Study
|
N/A | |
Completed |
NCT01675414 -
Understanding Gastrointestinal Conditions in Children With Autism Spectrum Disorder (ASD)
|
N/A | |
Not yet recruiting |
NCT00695812 -
The Development of Younger Siblings of Children With Autism Now at 10 Years of Age
|
N/A | |
Recruiting |
NCT05910502 -
Project AFECT (Autism Family Empowerment Coaching and Training Program)
|
N/A | |
Completed |
NCT02081027 -
Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders
|
Early Phase 1 | |
Completed |
NCT02797379 -
The Development of a Psychoeducational Tool to Manage Anxiety in People With Autism Spectrum Disorders
|
N/A | |
Terminated |
NCT01730079 -
Near Infrared Spectroscopy in Children With Autism and ADHD
|
||
Completed |
NCT01603225 -
Transcranial Direct Current Stimulation and Autism
|
||
Completed |
NCT01931033 -
An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders
|
N/A |